LENZ Therapeutics, Inc. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Form 8-K filed 2026-07-02 reports Item 5.02 event(s) concerning departure of director(s) or officer(s) and/or compensatory arrangements, with period of report 2026-06-30. The filing document references these items but the actual text content detailing specific names, amounts, dates, and arrangements is not provided in the header/metadata supplied.
Why this rating
Filing indicates officer/director change but lacks specific details (names, titles, severance amounts, effective dates). Without substantive disclosure, materiality cannot be assessed. Routine 8-K procedural filing.
Extracted items
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.